UroXatral launch
Executive Summary
Sanofi expects to launch UroXatral (once-daily alfuzosin) for benign prostatic hyperplasia treatment in 2003; Sanofi and SkyePharma received an "approvable" letter from FDA in October 2001 (1"The Pink Sheet" Oct. 15, 2001, In Brief)...
You may also be interested in...
SkyePharma/Sanofi UroXatral "approvable"
Sanofi-Synthelabo and SkyePharma expect to launch UroXatral (once-daily alfuzosin) in 2002, Sanofi says following Oct. 5 "approvable" letter from FDA. European version of benign prostatic hyperplasia treatment was approved in January as Xatral OD
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.